Found: 17
Select item for more details and to access through your institution.
Why do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug decisions in four European countries.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Direct cost of pars plana vitrectomy for the treatment of macular hole, epiretinal membrane and vitreomacular traction: a bottom-up approach.
- Published in:
- 2016
- By:
- Publication type:
- journal article
SCIENTIFIC AND SOCIAL VALUE JUDGMENTS FOR ORPHAN DRUGS IN HEALTH TECHNOLOGY ASSESSMENT.
- Published in:
- International Journal of Technology Assessment in Health Care, 2016, v. 32, n. 4, p. 218, doi. 10.1017/S0266462316000416
- By:
- Publication type:
- Article
SCIENTIFIC AND SOCIAL VALUE JUDGMENTS FOR ORPHAN DRUGS IN HEALTH TECHNOLOGY ASSESSMENT.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel.
- Published in:
- 2021
- By:
- Publication type:
- journal article
'Mapping' Health State Utility Values from Non-preference-Based Measures: A Systematic Literature Review in Rare Diseases.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Examining the impact of different country processes for appraising rare disease treatments: a case study analysis.
- Published in:
- 2021
- By:
- Publication type:
- journal article
The estimation of health state utility values in rare diseases: overview of existing techniques.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Improving Interpretation of Evidence Relating to Quality of Life in Health Technology Assessments of Rare Disease Treatments.
- Published in:
- Patient, 2023, v. 16, n. 1, p. 7, doi. 10.1007/s40271-022-00598-4
- By:
- Publication type:
- Article
The Use of Patient-Reported Outcome Measures in Rare Diseases and Implications for Health Technology Assessment.
- Published in:
- Patient, 2021, v. 14, n. 5, p. 485, doi. 10.1007/s40271-020-00493-w
- By:
- Publication type:
- Article
The estimation of health state utility values in rare diseases: do the approaches in submissions for NICE technology appraisals reflect the existing literature? A scoping review.
- Published in:
- European Journal of Health Economics, 2023, v. 24, n. 7, p. 1151, doi. 10.1007/s10198-022-01541-y
- By:
- Publication type:
- Article
Consideration of quality of life in the health technology assessments of rare disease treatments.
- Published in:
- European Journal of Health Economics, 2022, v. 23, n. 4, p. 645, doi. 10.1007/s10198-021-01387-w
- By:
- Publication type:
- Article
Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL).
- Published in:
- 2017
- By:
- Publication type:
- journal article
Social and economic costs and health-related quality of life in non-institutionalised patients with cystic fibrosis in the United Kingdom.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Price and reimbursement for orphan medicines and managed entry agreements: does Italy need a framework?
- Published in:
- Global & Regional Health Technology Assessment, 2021, v. 8, n. 1, p. 114, doi. 10.33393/grhta.2021.2278
- By:
- Publication type:
- Article
Are supplemental appraisal/reimbursement processes needed for rare disease treatments? An international comparison of country approaches.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Why do health technology assessment drug reimbursement recommendations differ between countries? A parallel convergent mixed methods study.
- Published in:
- 2020
- By:
- Publication type:
- journal article